Inizio launches Intelligent Congress: Turning medical event investment into measurable impact
May 12, 2026 | Congress, Pharma, healthcare
Inizio, the global commercialization partner to the health and life sciences industry, today announced the launch of Intelligent Congress – a connected, end-to-end solution designed to help pharma organizations maximize the value of congress investment and deliver measurable business impact.
Medical congresses remain one of the most critical data milestones in an asset’s development, providing valuable opportunities to translate scientific innovation into clinical practice. However, many organizations still approach congresses as standalone events, with fragmented planning across therapy area teams, limited alignment to overarching disease area objectives, and limited clarity on measuring success beyond immediate metrics.
By operating as a single, integrated partner across the full data and congress lifecycle, Inizio helps clients navigate complexity, align stakeholders, and gain clearer confidence in the impact of their congress investments. Our strength lies in an unmatched vantage point – combining deep, cross-functional expertise with end-to-end visibility across the product lifecycle.
Intelligent Congress is built on this foundation. Drawing on more than 30 years of experience across therapy areas, it unites strategy, experience design, delivery, and measurement into one cohesive model. This depth and breadth enable clients to move beyond fragmented, activity-based metrics and instead focus on what truly matters – meaningful shifts in HCP understanding, engagement, and behavior.
Discover how Intelligent Congress can help you create more strategic, measurable, and impactful HCP engagement. Visit our congress page or connect with the Inizio team at booth 21157 during the ASCO® Annual Meeting 2026 to see Intelligent Congress in action.
Read full article here.
This content was provided by Inizio
Company Details
Latest Content from Inizio
The Internet of Things
Evolution from man to machine
Therapy Watch expands its oncology portfolio
This month Therapy Watch Oncology will be expanding its portfolio with the addition of Squamous Cell Carcinoma of the Head and Neck (SCCHN). Therapy Watch SCCHN is part of a wider portfolio…
Time for a new language for asthma?
Despite the global advances made in the treatment for asthma, many studies have shown that asthma remains uncontrolled for a large proportion of patients, when assessed according to international guidelines….
Evaluating the impact of your medical congress presence…more cost effectively
Organising a company’s presence, not just logistically, but in terms of delivering key information, data and messages, is a massive part of some people’s workload at this time of year….
Delivering multi-stakeholder patient journey insights in oncology with creative outputs and data visualisation
Two clients were co-developing a product and needed to understand the patient journey in two areas of oncology, in order to identify the leverage points where they could provide an…
Webinar: Understanding Patient Willingness to Pay
What steps should pharma and medical device companies take to ensure they get their pricing strategy right in self-pay markets?
Research Partnership welcomes 22 new Graduates
As part of our continued growth, we are delighted to announce a new intake of 17 Research Analysts and 5 Fieldwork Project Coordinators into our annual market research graduate programme.http://www.researchpartnership.com/news/2016/09/new-graduates-2016/
Case study: Tracking a product launch in a dynamic and competitive market
With the imminent expected approval and launch of a new product, our client needed to conduct global tracking research to understand knowledge, perceptions, awareness and recall around their product and the quality…
Understanding the Chronic Disease Patient Journey in Emerging Markets
The benefits of understanding the patient journey are well documented in mature markets. But in emerging markets the patient journey is less understood. We recently presented a webinar hosted by…
Latest wave of Therapy Watch IBD to run this month
The IBD syndicated market tracker is part of our large auto-immune portfolio